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Background/aim: Biochemical, environmental, and genetic factors such as oxidative stress-induced DNA damage and homocysteine
(Hcy) accumulation in the blood are involved in the development and progression of ovarian cancer. This study measured some
biomarkers closely linked to the progression of ovarian cancer and also found their correlates.
Materials and methods: Thirty patients were diagnosed with ovarian cancer using pelvic examination, transvaginal ultrasound, and
cancer antibody (CA-125) measurement. Total oxidative stress (TOS), DNA damage, Hcy, malondialdehyde (MDA), total antioxidant
status (TAS), and other biochemical parameters were determined.
Results: TOS and DNA damage were positively and significantly correlated between themselves and were involved in causation of
tumors as reflected by significantly (P < 0.001) higher CA-125, erythrocyte sedimentation rate (ESR), creatinine, and C-reactive protein
(CRP) in both young and old patients. Both were significantly correlated with Hcy, LDL-cholesterol, alanine aminotransferase, aspartate
aminotransferase, CRP, MDA, and CA-125. However, they were negatively correlated with TAS. Thus, excessive inflammation and
oxidative stress caused an increase in DNA damage and enhanced Hcy content, leading to development of ovarian cancer.
Conclusion: This study suggests the use of antioxidants as drugs to reduce oxidative stress, DNA damage, and other causes of cancer
development
Key words: Antioxidants, DNA damage, CA-125, C-reactive protein, malondialdehyde, total antioxidant status, total oxidative stress

1. Introduction
Ovarian cancer is a silent killer, affecting a number of
women in both developed and developing countries
every year. To date there is no reliable way to screen
women for ovarian cancer in the developing world. Pelvic
examinations, transvaginal ultrasound, and blood tests
(CA-125) are the main ways used to diagnose ovarian
cancer (1). Diagnosis of this disease is not sought at its
early stage of development as the majority of women
(>85%) seek help when the disease has progressed
to stage III or stage IV as diagnosed by lymphatic,
intraperitoneal, or advanced stage of spreading in
stage III, in the far sites of the ovaries (stage IV), or in
the metastatic phase. This happens because of the lack
of visible symptoms of this disease in affected women.
There are no noninvasive techniques developed so far for
early stage diagnosis (2).
* Correspondence: shaziabukhari@gcuf.edu.pk

Ovarian cancer is the third most common fatal
gynecological disease amongst Pakistani women and
needs attention in order to have a healthy society. There
are numerous risk factors involved in the development of
this cancer. These include enhanced production of steroid
hormones, inflammation, infertility, excessive ovulations,
and nulliparity (3).
Production of reactive oxygen species (ROS) is
involved in creating oxidative stress in such patients. This
process may be linked with induction of carcinogenesis via
epigenetic and genetic mechanisms. There is an imbalance
in the production of prooxidants/antioxidants in various
cancer cells compared with that in normal cells (4). This
disturbed process may be a cause of inducing oncogenesis
in such patients. Oxidative stress may cause mutation in
cellular DNA. These aberrant mutations normally occur
in carcinogenesis and are a well-recognized phenomenon
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(5). These oxidative stress-induced DNA lesions (8-OHG) have been witnessed in various cancer types. It is
concluded from numerous studies that such breaks in DNA
are predominantly associated with the cancer initiation
process (4). Malondialdehyde (MDA) is a biomarker of
lipid peroxidation and oxidative stress. Elevated levels of
MDA have been observed to exist in the plasma of such
cancerous patients. Lower amounts of antioxidants also
cause increase in oxidative stress (6). Oxidative stress also
has a strong link with Hcy accumulation in the blood
stream. The Hcy level was elevated in the sera of the
majority of ovarian cancer patients (7).
Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) are elevated in patients with
ovarian cancer, and particularly in stage IV cancer
patients. Ovarian cancer causes severe inflammation.
C-reactive protein (CRP) is considered a test marker
of tumor development. It is produced in the liver in
response to inflammation (8). The association of many
of these parameters is not currently clear in the Pakistani
population. Therefore, this study was designed to evaluate
these risk factors in general Pakistani women. This study
also measured known biomarkers, closely linked to
the progression of ovarian cancer, and computed their
correlation.
2. Materials and methods
2.1. Subjects
The fasting blood samples of 30 ovarian cancer patients
and 30 healthy volunteers (of the same age and genetic
background) were collected. The participants were
recruited from Punjab Institute of Nuclear Medicine
Allied Hospital, Faisalabad. Informed consent was
obtained from all participants. These patients visited the
hospitals for routine check-ups and were picked randomly
from in and around Faisalabad. All participants were of
middle socioeconomic background. Patients suffering
from pelvic pressure and having excessive vaginal bleeding
were checked for CA-125 antibody, lactate dehydrogenase,
and transvaginal ultrasound. Color flow Doppler tests
and biopsies were also performed to confirm ovarian
cancer in patients. Malignant cancer was confirmed by
magnetic resonance imaging. Fifteen patients had stage
III cancer, in which the cancer was confined to ovaries
only, while in 15 others the cancer had distant metastasis
and migrated to the liver. Confirmations were made by
gynecologists and oncologists. Body mass index (BMI,
kg/m2), blood pressure, pulse rate, and body temperature
were recorded. Patients who experienced complications
were discontinued from the study.
2.2. Design
The blood pressure of young and old participants
was measured by using sphygmomanometer after the
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individual had rested for 10 min in a quiet room. The
readings were recorded as systolic and diastolic blood
pressure. The weight of each individual was taken with
the help of a weighing machine. Height in meters was
recorded with the help of a measuring tape when subjected
were barefoot. Cut-off values were from published clinical
values. Efforts were made to match the patients and the
controls for any potential confounding factors, namely age
and socioeconomic condition. A total of 60 blood samples
were collected between 0800 and 0900 hours in a precooled
test tube from normal and cancerous patients. Tubes were
centrifuged at 769× g for 15 min. Serum was separated
and stored in small aliquots at –20 °C till analysis. Another
sample with anticoagulant using heparin (1%) was also
taken for packed cell volume, erythrocyte sedimentation
rate (ESR), and hemoglobin.
2.3. Analytical methods
All tests were performed in Punjab Institute of Nuclear
Medicine Clinical Laboratories and Government
College University Faisalabad Laboratories using their
standard protocols. The concentration of hemoglobin
was determined using colorimetric assay kit (Cayman
Chemical Company, item # 700540) following the
manufacturer’s instructions. The concentrations of
cholesterol and triglycerides were determined using
enzymatic kits (Randox Laboratory) on a Hitachi 704
analyzer using standard methods. The precision limits for
determination of total cholesterol and total triglycerides
varied between 1.3% and 2.4% and between 1.9% and 3.5%
per run, respectively.
Serum HDL-cholesterol level was determined using
commercially available kit (Cat No. D1H20-400, Diasis
Diagnostik) following the instruction provided by the
suppliers. This kit works on the principle of blocking apoB
containing proteins by blocking the agent present in the
kit. In this way only HDL-cholesterol is detected under the
assay working conditions. HDL-cholesterol in serum was
precipitated with phosphotungstic acid in the presence of
magnesium ions. The concentration of LDL-cholesterol
was calculated using the Friedewald formula.
Serum glucose test was performed using Human kit
(Human, GmbH 65205) and a spectrophotometer at
545 nm. The plasma total antioxidant status (TAS) level
was measured using a commercial kit (Cell Biolab, cat
no STA-360). In this assay, free radicals are produced
by hydroxyl radicals and the antioxidative effect of the
sample against them is measured. We followed this
method according to the manufacturer’s instructions and
all assays showed excellent precision values (lower than
3%). The results were expressed as mmol Trolox equiv.L–1
as mentioned by above suppliers.
Serum total oxidative stress (TOS) levels were
determined using an automated measurement method
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developed by Erel (9). Oxidants present in the test or the
standard sample oxidize the ferrous ions-o-dianisidine
complex to ferric ions, which make a colored complex
with xylenol orange in the acidic medium. The color
intensity is directly related to the total amount of oxidants
present in the sample or standard. The assay was calibrated
with hydrogen peroxide, and the results were expressed in
terms of µM hydrogen peroxide equivalent per liter (µmol
H2O2 equiv. L–1).
Plasma
MDA
levels
were
quantified
spectrophotometer at 532 nm as described by the
suppliers of commercial kit (Cayman Chemical
Company, item no. 10009055). One milliliter of working
reagent was taken in tubes marked as blank, sample, and
standard, respectively. Then 10 µL of sample or standard
was added to the respective tubes, mixed well, and
incubated at 25 °C for 30 min. Lipid peroxides in plasma
were estimated colorimetrically. The absorbance of clear
supernatant was measured against reference blank at
535 nm spectrophotometrically, employing the molar
absorption coefficient of 1.56 × 105 M−1cm−1.
Plasma Hcy was measured by Hcy microtiter plate
assay (7) from control and ovarian cancer patients
using a commercial kit (Diazyme) as per manufacturer’s
instructions. Briefly, plasma samples were prepared in
polyethylene culture tubes with a reducing agents, tris
(2-carboxyethyl) phosphine hydrochloride, to reduce the
protein bound Hcy to free Hcy that was subsequently
converted to S-adenosyl-L-Hcy (SAH) by SAH-hydrolyase
and quantified by horseradish peroxidase (HRP-SAH)
competitive assay.
DNA damage was measured in serum using EIA kit
(Cell Biolab,Inc., Cat. STA-320) as described previously
(10). Briefly, the quantity of 8-Hydroxy-2’deoxyguanosine
(8-OHdG) in an unknown sample was determined by
comparing its absorbance with that of a known 8-OHdG
standard curve as per manufacturer’s instructions. The
laboratory performed strict external and internal quality
control tests. Reagents for calibration of instruments were
supplied by their manufacturers.
Table 1.

Serum urea was measured by using commercially
available kit (Cat No. UR 222; Randox Laboratories)
and following manufacturer’s instructions. Serum AST
(Crescent Diagnostics Cat No. CZ 904 C) and ALT
(Crescent Diagnostics Cat No. CZ 902 C) were determined
by colorimetric method. The serum CRP level was
determined by CRP ELISA Human (Cat. No. CYT298,
Merck Millipore) kit test. CA-125 was measured by using
ovarian cancer antigen CA-125 ELISA kit (Phoenex cat
#KA0205). All the work was done in highly sterilized
conditions. Strict external and internal quality control
tests were performed.
2.4. Statistical and sensitivity analyses
The collected data were subjected to calculations of means
± standard deviation (SD). To calculate the differences
between normal and ovarian cancerous patients of young
and old age, data were analyzed by two-way ANOVA
(11). In case of significant differences, Duncan’s multiple
range test was applied (12) using GraphPad 3.0 software.
Spearman’s correlation coefficients between different
anthropometric data, biochemical profiles, and their
effects in term of TOS and oxidative DNA damage were
also determined using the above-mentioned software.
3. Results
General anthropometric characteristics of the subjects
are shown in Table 1. There was no significant difference
in BMI (P = 0.5865) between the controls and patients.
Similarly, SBP (P = 0.5088) and DBP (P = 0.1445) also
were not significantly different in the patients as compared
with the controls. The young and old patients had a mean
age of 24 ± 4 and 50 ± 7 years, respectively. In younger
patients ovarian cancer was located in the ovaries while in
older patients it was found to be in the metastatic phase.
Serum hematological, biochemical, tumor, and health
biomarkers of young and old normal and cancerous
patients are shown in Table 2. Mean serum ESR was
significantly higher (P < 0.0001) in older patients
with ovarian cancer, followed by younger patients. All
healthy participants had normal values. Hemoglobin

Anthropometric parameters of normal and cancerous patients.

Parameters

Normal

Ovarian cancer

P-value

Young N = 15

Old N = 15

Young N = 15

Old N = 15

BMI (kg/m2)

22.33 ± 1.92

24.83 ± 2.03

21.23 ± 1.85

24.06 ± 1.78

0.5865

Systolic blood pressure (SBP; mm/Hg)

120.0 ± 2.0

126.0 ± 2.45

123.0 ± 3.9

119.0 ± 6.23

0.5088

Diastolic blood pressure (DBP; mm/Hg) 82.83 ± 0.70

87.17 ± 0.60

81.0 ± 3.72

78.0 ± 4.0

0.1445

Age (Years)

50 ± 7

24 ± 4

50 ± 7

N.D.

24 ± 4

N.D. = not determined.

585

BUKHARI et al. / Turk J Med Sci
Table 2. Serum hematological, biochemistry, tumor, and health biomarkers of young and old normal and cancerous patients.
Parameters

Normal

Ovarian cancer

P-value

Young

Old

Young

Old

Erythrocyte sedimentation rate (ESR; mm/h)

2.50 ± 0.50

4.00 ± 0.32

41 ± 1.91

62 ± 6.23

<0.0001

Hemoglobin (mg/dL)

12.31 ± 0.23

12.10 ± 0.17

11.0 ± 0.6

10.9 ± 0.4

0.6602

Creatinine (mg/dL)

0.70 ± 0.44

1.0 ± 0.02

0.76 ± 0.0678

2.818 ± 0.0568

0.0001

Alanine aminotransferase (ALT; U/L)

11.00 ± 0.81

22.83 ± 2.30

42.6 ± 8.78

46.7 ± 8.3

<0.0001

Aspartate aminotransferase (AST; U/L)

5.83 ± 0.54

14.00 ± 1.23

41.0 ± 6.6

64.4 ± 8.9

<0.0001

CRP (mg/L)

2.45 ± 0.45

4.02 ± 0.99

7.2 ± 0.735

14.4 ± 2.48

<0.0001

CA-125 (U/mL)

2.61 ± 0.12

3.45 ± 1.2

560 ± 120

690 ± 130

0.0230

Cholesterol (mg/dL)

150.25 ± 0.12

176.57 ± 0.08

75.4 ± 17.7

112.8 ± 7.52

0.0279

Triglyceride (mg/L)

81.13 ± 0.08

123.78 ± 0.04

135.0 ± 7.83

126.0 ± 18.1

<0.0001

HDL-Cholesterol (mg/dL)

37.98 ± 0.05

54.41 ± 0.11

27.8 ± 7.61

23.4 ± 4.12

<0.0001

LDL-Cholesterol (mg/dL)

87.99 ± 0.05

117.41 ± 0.12

124.8 ± 13.9

131.9 ± 10.5

<0.0001

Homocysteine (µmol/L)

8.5 ± 0.29

13.0 ± 0.51

26.45 ± 5.78

30.34 ± 9.89

<0.0001

Total oxidant status (TOS; (µmol hydrogen per oxide Equv./L) 7.71 ± 0.42

13.26 ± 0.32

103.22 ± 5.87

127.98 ± 6.77

<0.0001

Malonodialdehyde (MDA; (µmol/L)

0.26 ± 0.01

0.54 ± 0.02

13.18 ± 2.0

15.23 ± 1.8

<0.0001

Total antioxidant status (TAS; mmol/Trolox)

1.6 ± 0.03

1.36 ± 0.02

0.35 ± 0.02

0.24 ± 0.03

<0.0001

DNA damage (µm)

1.2 ± 0.5

1.32 ± 1.11

25.43 ± 0.84

45.25 ± 1.12

<0.0001

Each value is a mean ± SD among the number of subjects in each row.

was nonsignificantly lower in older cancer patients (P =
0.6602), followed by younger cancer patients. Healthy
participants had normal hemoglobin levels. Mean serum
glucose was nonsignificantly higher (P = 0.1201) in cancer
patients. Creatinine was significantly higher (P = 0.0001)
in older cancer patients, followed by younger patients. The
control participants had normal amounts of creatinine.
Levels of ALT and AST were significantly higher
(P > 0.0001) in cancer patients. Mean serum CRP was
extremely high in older cancer patients (P < 0.001) as
compared with that of healthy older participants. However,
it was not significant in younger cancer patients (P > 0.05)
as compared with that of healthy participants. On the
whole, the level of CRP was significantly higher in ovarian
cancer patients. CA-125 was significantly higher in older
individuals with cancer as compared with that of healthy
individuals. All cancer patients, irrespective of age, showed
a significant increase in CA-125 levels (P = 0.0230). Urea
was nonsignificantly higher in ovarian cancer patients (P >
0.05). Control participants had normal levels of urea.
The cholesterol did not follow any linked trend. The
cholesterol was observed significantly lower (P < 0.05)
in young patients suffering from ovarian cancer. The
triglyceride levels were significantly higher in younger
cancer patients (P < 0.001) as compared with those in
healthy young participants. Levels of HDL-cholesterol were
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extremely significantly lower in all patients (P < 0.0001),
while LDL-cholesterol was significantly higher (P < 0.0001)
in ovarian cancer patients. Levels of homocysteine and total
oxidant status were significantly higher in all patients (P <
0.0001). MDA levels were significantly higher (P < 0.0001)
in cancer patients as compared with those of healthy
participants. Total antioxidant status was significantly
higher in all control participants than in cancer patients (P
< 0.0001). DNA damage was significantly higher in older
patients compared with healthy older individuals. DNA
damage was also significantly higher in younger cancer
patients (P < 0.05).
We performed the correlation analysis between
TOS and all studied parameters (Table 3) in healthy
individuals and cancer patients. The results showed that
TOS was significantly and positively correlated with LDLcholesterol (P < 0.001), ALT (P < 0.005), AST (P < 0.003),
CRP (P < 0.0051), DNA damage (P < 0.003), MDA (P <
0.004), Hcy (P < 0.004), and CA-125 (P < 0.001). However,
it was significantly and negatively correlated with TAS (P
< 0.002). TOS was not significantly correlated with any of
the studied parameters in control participants.
The correlation of DNA damage with all studied
parameters is shown in Table 4. DNA damage (%) was
positively and significantly correlated with homocysteine
(P < 0.0001), LDL-cholesterol (P < 0.001), ALT (P <
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Table 3. Correlation coefficients of oxidative stress in relation with other parameters of normal and cancerous individuals.
Parameters

Normal

P-value

Patients

P-value

LDL- cholesterol (mg/dL)

0.133

NS

0.921

0.001

Alanine aminotransferase (ALT; U/L)

0.121

NS

0.612

0.005

Aspartate aminotransferase (AST; U/L)

0.672

NS

0.711

0.003

CRP (mg/dL)

0.795

NS

0.691

0.005

DNA damage

0.321

NS

0.886

0.003

Malondialdehyde (MDA; (µmol/L)

0.320

NS

0.792

0.004

Homocysteine (µmol/L)

0.089

NS

0.687

0.004

CA-125 (U/mL)

0.130

NS

0.990

0.001

Total antioxidant status (TAS; mmol/Trolox)

0.018

NS

–0.979

0.002

NS is for nonsignificant (P > 0.05).

Table 4. Correlation coefficients of DNA damage in relation with other parameters of normal and cancerous individuals.
Parameters

Normal

P-value

Patients

P-value

LDL- cholesterol (mg/dL)

0.133

NS

1.00

0.001

Alanine aminotransferase (ALT; U/L)

0.121

NS

1.00

0.0001

Aspartate aminotransferase (AST; U/L)

0.672

NS

1.00

0.0001

CRP (mg/dL)

0.795

NS

0.991

0.001

Malondialdehyde (MDA; (µmol/L)

0.320

NS

0.999

0.0001

Homocysteine (µmol/L)

0.089

NS

1.00

0.0001

CA-125 (U/mL)

0.130

NS

1.000

0.001

Total antioxidant status (TAS; mmol/Trolox)

0.018

NS

–1.000

0.0001

0.0001), AST (P < 0.0001), CRP (P < 0.001), TOS (P <
0.0001), MDA (P < 0.0001), and CA-125 (P < 0.001).
However, it was negatively significantly correlated with
TAS (P < 0.001). All other studied parameters did not
show any significant correlation with DNA damage (P >
0.05) in normal subjects.
4. Discussion
Ovarian cancer, one of the most common malignant
ailments in women, is a major public health problem in
both developing and developed countries (13). Oxidative
stress has become a focus of intense interest since it is
involved in the causation and progression of many deadly
cancers throughout the world (5). Quality of life is a new
and undervalued issue in Pakistan with relatively little
attention being paid to measuring the subjective health
status of Pakistan’s general population. BMI was normal
in ovarian cancer patients, similar to that of healthy
individuals and was not a risk factor for ovarian cancer.
Likewise, systolic and diastolic blood pressure was normal
in individuals diagnosed with ovarian cancer. Some studies

also reported an increased risk of ovarian cancer among
obese women (14,15). The results from this study are in
support of Greggi et al. (15) who have found no association
between obesity and ovarian cancer. Socioeconomic and
environmental factors, as well as psychosocial stressors
could be responsible for these differences.
Hemoglobin was lower in older cancer patients, but the
low levels were not significantly (P = 0.6602) different; low
levels of hemoglobin can be a side effect of chemotherapy.
The associations of high glucose levels with ovarian cancer
risk are not currently clear in the Pakistani population.
The current study did not show any positive association
between glucose levels and ovarian cancer. The results of
this study supported the results of Lambe et al. (16), who
found no associations between glucose levels and ovarian
cancer risk.
Creatinine level was significantly higher (P = 0.0001)
in older cancer patients as compared with that in healthy
individuals. The higher creatinine levels observed in
patients may be due to the drugs used by ovarian cancer
patients as treatment. Serum urea levels were normal in in
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all participants. The concentrations of AST and ALT are
used for detecting hepatocellular injury and may help in
monitoring the status of the liver. In the current study, ALT
and AST were significantly higher in some cancer patients.
Both enzymes tend to increase in many hepatic diseases
and have limited value in providing a differential diagnosis.
However, aminotransferases are considered useful in
differentiating hepatocellular from cholestatic forms of
liver injury. AST activity is related to damage of cells in
the kidney, heart, pancreas, and erythrocytes (3). Chronic
inflammation plays a role in ovarian carcinogenesis (18).
In the current study, CRP levels were significantly (P <
0.0001) elevated in cancer patients as compared with those
of healthy individuals. ESR is a nonspecific measure of
inflammation. The levels of ESR were significantly higher
(P < 0.0001) in older cancer patients. Thus, the current
study supports the role of inflammation in ovarian cancer.
CA-125 is best known as a marker for ovarian cancer
(19). Its levels are elevated in ovarian cancer or in cases
of inflammation. The current study shows a significantly
higher (P = 0.0230) increase in its levels in cancer patients
as compared with healthy individuals.
Overall mean serum LDL increased, while cholesterol,
triglycerides and HDL were significantly lower in cancer
patients. The current study supports that low levels of
HDL can be linked with the incidence of ovarian cancer.
Memon et al. (20) also found inverse relation of cholesterol
with increased incidence of cancer.
In the current study, the levels of Hcy were significantly
higher (P < 0.0001) in ovarian cancer patients. High levels
of Hcy are believed to promote the formation of oxidation
products, which have the capacity to damage endothelial
cells. It was also reported by Corona et al. (7) that higher
total Hcy concentration was significantly higher in ovarian
carcinoma patients.
In the present study, TOS was significantly higher (P <
0.0001) in cancer patients as compared with that of healthy
individuals. Senthil et al. (6) also found increased levels
of oxidative stress in ovarian cancer patients. MDA levels
were significantly higher (P < 0.0001) in cancer patients
as compared with those of healthy individuals. Thus, both
parameters of oxidative stress increased in cancer patients.
Klaunig and Kamendulis (5) also provided evidence of
cellular oxidant involvement in the carcinogenesis process.
8-OHdG is a marker of oxidative DNA damage.
The current study shows a highly significant increase (P
< 0.0001) in DNA damage of ovarian cancer patients as
compared with that of healthy individuals. This DNA
damage can be due to oxidative stress. The current
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study supports the findings reported in Bandebuche and
Melinkeri (13) that DNA damage plays a major role in
ovarian cancer initiation and progression.
The current study shows a highly significant (P <
0.0001) decrease in TAS, which may be induced by
imbalance between TOS and body’s defense mechanisms.
The low levels of antioxidants in the plasma of ovarian
cancer patients were also found by Senthil et al. (6), and
may be due to their increased utilization to inactivate lipid
peroxides as well as their sequestration by tumor cells. This
evidence suggests that TAS can be monitored as a marker
in order to understand progression of ovarian cancer.
The correlation of TOS and DNA damage with
other parameters shows that they both were positively
correlated with homocysteine, LDL-cholesterol, ALT, AST,
CRP, MDA, and CA-125. However, both were negatively
correlated with TAS. These results show that excessive
inflammation, as indicated by significantly higher levels
of CRP, CA-125, creatinine, tissue damage, and oxidative
stress, and low levels of antioxidants cause an increase in
DNA damage. The study also shows that there is a direct
relationship between oxidative stress and tumor markers
(CA-125 and CRP). In healthy participants these were not
related to the above parameters.
In conclusion, this study shows that increase in
oxidative stress enhances DNA damage, elevates
homocysteine levels, and reduces total antioxidant status
in the blood samples of ovarian cancer patients. These
indices may be considered as causative agents in ovarian
cancer in both younger and older patients. The detection
of Hcy, CA-125, CRP, and transaminases in patients’ blood
samples gave information about the presence of tumors,
but they are inconclusive in detecting a particular cancer.
Further work is needed to enhance our ability for its
detection in the early stages. More comprehensive study
of the relationship between ROS and the body defense
mechanism in carcinogenesis may greatly improve our
ability to develop interventions to decrease oxidative stress
in cancer patients. Defining the ovarian cancer risk profiles
will help public health authorities to better understand and
target the disease. Extensive research in this field would
enable the medical community to develop new drugs to
more effectively treat ovarian cancer patients.
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